HALO - Halozyme Therapeutics Non-GAAP EPS of $0.79 beats by $0.09 revenue of $195.88M misses by $3.77M
2024-05-07 16:03:31 ET
More on Halozyme Therapeutics
- Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
- Halozyme Therapeutics, Inc. (HALO) Q4 2023 Earnings Call Transcript
- Halozyme Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Halozyme Therapeutics Q1 2024 Earnings Preview
- FDA accepts Bristol Myers application for injected Opdivo